Generic placeholder image

Current Vascular Pharmacology

Eiditor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

The Role of Trimetazidine After Acute Myocardial Infarction

Author(s): Maciej Banach, Jacek Rysz, Aleksander Goch, Dimitri P. Mikhailidis and Giuseppe M.C. Rosano

Volume 6 , Issue 4 , 2008

Page: [282 - 291] Pages: 10

DOI: 10.2174/157016108785909788

Price: $58

Abstract

“Metabolic treatment” involves the use of drugs to improve cardiomyocyte function. Trimetazidine is the most investigated drugs in this group. The ESC 2006 guidelines on the management of patients with stable angina mention the efficacy of metabolic treatment in improving physical efficiency and decreasing the recurrence of pain. The available data suggest that combined therapy of trimetazidine and haemodynamic drugs is an effective antianginal treatment that reduces the risk of pain recurrence (in as many as 64% of patients). The most recent studies also suggest that trimetazidine might be effective in patients with acute coronary syndromes, ischemic cardiomyopathy and heart failure. However, while trimetazidine has shown beneficial effects on surrogate endpoints in several small trials its effect on cardiovascular events is uncertain. Further large randomized studies are needed before its effects on cardiovascular events can be evaluated.

Keywords: Acute coronary syndromes, metabolic treatment, trimetazidine


Rights & Permissions Print Export Cite as
Article Metrics
4
Related Journals
Related eBooks
Related Articles
© 2019 Bentham Science Publishers